The raised full-year EPS guidance and accelerating core growth excluding respiratory (5.5%) signal improving end-market trends. Watch Q4 for continued bioprocessing momentum and Life Sciences recovery, which could drive further upside to the newly raised $8.57-$8.62 range.
Price Chart
Executive Summary
Danaher reported Q3 2026 results with revenue of $6.6B (+8.5% YoY) and non-GAAP adjusted EPS of $2.11 (+11.5% YoY), beating Street consensus of $1.92. The company raised its full-year 2026 adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60, citing accelerating core growth excluding respiratory and strong DBS-driven execution.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $6.6B, +8.5% YoY
- Non-GAAP adjusted diluted EPS $2.11, +11.5% YoY, above consensus $1.92
- GAAP diluted EPS $1.71, +34.5% YoY
- Non-GAAP core revenue excluding respiratory +5.5% YoY
- Full-year 2026 adjusted EPS guidance raised to $8.57-$8.62 from $8.45-$8.60
- Operating cash flow $1.9B, free cash flow $1.6B
- Biotechnology core sales +5.0%, Life Sciences +4.5%, Diagnostics +0.5%
- Diagnostics total sales +17.0% GAAP, boosted by respiratory testing
Financial Impact
Revenue $6.6B vs consensus $7.49B (GAAP miss), but adjusted EPS $2.11 beat consensus $1.92 by 9.9%
Risk Factors
- Respiratory revenue headwind of 150bps in Q4 could pressure reported growth
- Interest expense increased to $135M from $67M YoY due to Masimo acquisition debt
- GAAP revenue of $6.6B missed consensus of $7.49B, though the miss is largely due to acquisition accounting adjustments
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000313616-26-000201 |
| Document: dhr-20261021.htm | 0000313616-26-000201 |
| Document: 0000313616-26-000201-index-headers.html | 0000313616-26-000201 |
| Document: 0000313616-26-000201-index.html | 0000313616-26-000201 |
| Document: 0000313616-26-000201.txt | 0000313616-26-000201 |
| 8-K Data (Synthetic) | 0000313616-26-000201 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Institutional Cluster | $230.50 $232.97 | ▲ +1.07% | ▲ +0.36% | $232.65 (+0.93%) |
Oct 21, 2026 6d ago | Press Release | $233.86 $229.75 | ▼ −1.76% | ▼ −0.58% | $232.65 (−0.52%) |
Oct 20, 2026 6d ago | 8-K | $233.86 $229.75 | ▼ −1.76% | ▼ −0.58% | $232.65 (−0.52%) |
Oct 14, 2026 13d ago | Press Release | $224.69 $231.50 | ▲ +3.03% | ▲ +2.75% | $232.65 (+3.54%) |
Oct 13, 2026 14d ago | 8-K | $222.84 $224.69 | ▲ +0.83% | ▲ +1.91% | $232.65 (+4.40%) |
Sep 22, 2026 4w ago | Press Release | $221.56 $223.77 | ▲ +1.00% | ▲ +1.08% | $232.65 (+5.01%) |
Sep 15, 2026 5w ago | Press Release | $208.36 $212.50 | ▲ +1.99% | ▲ +0.85% | $232.65 (+11.66%) |
Aug 17, 2026 10w ago | Court Ruling | $199.23 $211.13 | ▲ +5.97% | ▲ +5.76% | $232.65 (+16.78%) |
Jul 21, 2026 14w ago | Press Release | $179.01 $179.14 | ▲ +0.07% | ▲ +0.19% | $232.65 (+29.96%) |
Jul 17, 2026 14w ago | Court Ruling | $201.11 $179.01 | ▼ −10.99% | ▼ −11.82% | $232.65 (+15.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers